PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
01-Sep-2022 MeVis Medical Solutions AG: Raising forecast for the current fiscal year MeVis Medical Solutions AG
01-Sep-2022 EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union Moderna, Inc.
01-Sep-2022 Brainomix's AI Software to be Rolled Out Across Hungary’s Entire National Healthcare System to Improve Stroke Care Brainomix
01-Sep-2022 Kaiku Health to improve cancer care through partnership with global medicines company Kaiku Health
01-Sep-2022 Biocomposites to present latest STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting Biocomposites
01-Sep-2022 Notice of AGM Proposed new 2022 Long Term Incentive Plan Spectral MD Holdings
01-Sep-2022 Calibre Scientific Acquires Achrom, a Distributor of Chromatography Consumables and Equipment in Benelux Calibre Scientific
01-Sep-2022 XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) Sanofi
01-Sep-2022 NuCana to Participate in Citi's 17th Annual BioPharma Conference NuCana
01-Sep-2022 OPTIMA pharma looks back on a successful ACHEMA Optima Pharma
01-Sep-2022 ProtonDx’s Dragonfly Diagnostic System Successfully Deployed at the 2022 Commonwealth Games ProtonDx
01-Sep-2022 PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022 PharmaSGP Holding SE
01-Sep-2022 APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill APONTIS PHARMA AG
01-Sep-2022 Zur Rose Group successfully completes placement of approx. CHF 95 million Convertible Bonds and the approx. CHF 44 million Capital Increase by way of an accelerated book building process Zur Rose Group AG
31-Aug-2022 MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters MorphoSys AG
31-Aug-2022 Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. CHF 50 million Capital Increase by way of an accelerated book building process Zur Rose Group AG
31-Aug-2022 EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395 B3C newswire
31-Aug-2022 PAION AG reports financial results for the first half-year 2022 PAION AG
31-Aug-2022 Emactuzumab designated as an Orphan Medicinal Product in Europe SynOx Therapeutics Limited
31-Aug-2022 ProtonDx’s Dragonfly Diagnostic System Successfully Deployed at the 2022 Commonwealth Games B3C newswire